Cleveland Clinic Receives $2.9 Million for Additional Research on Emerging Tick-borne Virus Pathogen
09/15/2022

Dr. Jae Jung will study the natural course of infection and viral reassortment of the emerging pathogen, Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV).

Read More

 

Cleveland Clinic Appoints Ted Ross, PhD, as Global Director of Vaccine Development
04/28/2022

In this newly created role, he will lead the development of novel vaccine platforms for a variety of infectious diseases, including influenza, HIV and COVID-19.

Read More

 

First Research Published Using Cleveland Clinic’s COVID-19 Study Samples Provides Glimpse into Potential New Treatments
04/07/2022

Dr. Jung and his team of researchers published the novel COVID-19 study, which details the critical role viral gene ORF8 plays in infection and outcomes rates, using samples from Cleveland Clinic’s BioRepository.

Read More

 

COVID-19 Infection During Pregnancy Leads to Distinct Immune Changes in Mothers and Babies
11/19/2021

Dr. Jung’s team studied blood samples collected from mothers with COVID-19 and their infant children who were exposed to SARS-CoV-2 to understand how infection modulates the expression of different inflammatory molecules.

Read More

 

Study Reveals Cause of Common Zika Virus Birth Defect
01/28/2021

Dr. Jung and his team defined the molecular mechanisms that underlie fetal brain calcification caused by Zika virus infection, most notably identifying the role of the protease NS3 in driving the virus-induced abnormal brain development.

Read More